Ebola Report by Joel Lord

VRM: Ebola Report
20th October 2014 - By Joel Lord



Another season of fear-mongering headlines & Government Health Department-spun pronouncements is upon us; our communities faced with a seemingly imminent (manufactured) health crisis being forced down our collective throats.

“As the (Ebola) epidemic gets more and more formidable and in some cases out of control it is quite conceivable, if not likely, that we may need to deploy the vaccine to the entire country to be able to shut the epidemic down. That is clearly a possibility.” U.S. National Institute for Allergy and Infectious Diseases (October 06, 2014)

The benchmark of sound journalism & good detective work in this field depends on the weight of scientific evidence presented, the accuracy of the data, and the ability to distinguish verifiable truth from (Pharmaceutical & Vaccine Industry) promulgated lies & misinformation – something clearly out of step with the Mainstream Media protocols of cover-up & deception.

We’ve been here before. History is predictably repeating itself…again.

Once again, as in 2009, the WHO are purposefully inflating the numbers of victims here, to ensure the maximum fear factor is felt throughout our communities. Until those clinics & hospitals impacted by this crisis release the actual (post mortem) laboratory results, any statistics being foisted on us represent nothing more than speculation at best.

‘These (Ebola) numbers are subject to change due to on-­going reclassification, retrospective investigation and availability of laboratory results…Work is also ongoing to resolve discrepancies between different sources of data, which may lead to a revision of the numbers of cases and deaths in the future.‘ WHO disclaimer

During the 2009 (CDC bio-laboratory produced) Pandemic. the WHO routinely exaggerated the overall death toll (attributable to H1N1); by including any/all cases associated with Flu-like symptoms – regardless of the fact that the VAST majority of victims ultimately died as a result of compromised immunity and/or pre-existing medical conditions. H1N1 was merely a blip on the radar, by all accounts a comparably mild seasonal flu.

Communities around the world were manipulated constantly by Mainstream Media outlets (in lock-step with the WHO & spineless Government health departments), via an ongoing barrage of misinformation, negative hype & fear-mongering propaganda. By the time all the dust settled it was unanimously determined by most experts in the scientific arena, “H1N1 has ultimately turned out to be, from a pandemic perspective, a dud.”

Therefore, It’s vitally important to analyze the current Ebola scare objectively.



So what, exactly, are we dealing with here? Is this, indeed, a legitimate (naturally occurring) catastrophe of unprecedented proportions we see unfolding? Is the Ebola Virus that serious a threat vs. a manufactured crisis? Or are we being deceived by a multi-billion dollar Industry, beholden to the Military Industrial Complex, bent on establishing a universal 99% “herd immunity” policy – the precursor to an eventual Government lock-down on individual freedom to choose, the official implementation of mandatory vaccinations across the board?

The recent Ebola outbreak in Africa coincides with a massive Meningitis Vaccine campaign targeting “150 million Africans”, many throughout Guinea & Nigeria.

The low-budget vaccine, MenAfriVac®, (less than US$0.50 per dose) was “kept outside the cold chain for up to four days at up to 40°C”.

Neighboring Liberia & Sierra Leone, both primary epicenters, were recently subject to the “largest ever Yellow Fever Immunization Program” conducted in that region – an estimated 12 million locals impacted (infected) by the compound shot.

Why has the Ebola virus suddenly erupted in a region of Africa known as the “Meningitis Belt” (comprising all four countries affected – Guinea, Liberia, Nigeria & Sierra Leone)?

Because the WHO & CDC are deliberately trying to cover up their bloody tracks.

This supposed outbreak of Ebola bares all the hallmarks of a rarified, virulent strain of bacterial Meningitis, ‘Acute fulminating Meningococcal Septicemia’, also known as ‘Waterhouse-Friderichsen Syndrome’, a virulent form of bacterial meningitis marked by extreme vomiting, hemorrhaging – excessive bleeding around the eyes & mouth, severe blackish bruising on the arms & legs, leading to Septic shock and potentially even death. These acute symptoms closely resemble those seen in Ebola victims.

Could this be yet another case of a dangerous, untested vaccine triggering a tsunami of viral & bacterial mutations, in impoverished regions?

Waterhouse-Friderichsen Syndrome: ‘‘The prodromal symptoms were similar to those encountered in any respiratory infection, consisting of headache, chilly sensations, muscular pains and malaise. The onset of the bacteremia was sudden and dramatic. The most striking features were the profound shock and the petechial eruption, which in the course of a few hours became purpuric…This condition gradually progressed until numerous coarse, bubbling rales could be heard over both lung fields. With the appearance of frank pulmonary edema terminally, the patient lapsed into coma and died shortly thereafter.‘

Meningococcal Septicemia (Septic shock): ‘The hallmarks of severe sepsis and septic shock are changes that occur at the microvascular and cellular level with diffuse activation of inflammatory and coagulation cascades, vasodilation and vascular maldistribution, capillary endothelial leakage, and dysfunctional utilization of oxygen and nutrients at the cellular level. The challenge for clinicians is to recognize that this process is under way when it may not be clearly manifested in the vital signs or clinical examination.‘ Andre Kalil, MD, MPH Professor of Medicine, Department of Medicine, Section of Infectious Diseases; Director, Transplant ID Program, University of Nebraska Medical Center

Note: ‘DIC (Disseminated intravascular coagulation), is most commonly observed in severe sepsis and septic shock. Indeed, the development and severity of DIC correlate with mortality in severe sepsis. Although bacteremia, including both gram-positive and gram-negative organisms, is most commonly associated with DIC, other organisms (eg, viruses, fungi, and parasites) may also cause DIC.

DIC exists in both acute and chronic forms. Acute DIC develops when sudden exposure of blood to procoagulants (eg, tissue factor [TF], or tissue thromboplastin) generates intravascular coagulation. Compensatory hemostatic mechanisms are quickly overwhelmed, and, as a consequence, a severe consumptive coagulopathy leading to hemorrhage develops. Abnormalities of blood coagulation parameters are readily identified, and organ failure frequently results.‘ Marcel M Levi, MD Dean, Academic Medical Center, University of Amsterdam, The Netherlands

A Virus (such as Ebola) is defined as a microorganism, consisting of strands of RNA/DNA ‘smaller than a bacterium that cannot grow or reproduce apart from a living cell. A virus invades living cells and uses their chemical machinery to keep itself alive and to replicate itself. It may reproduce with fidelity or with errors (mutations); this ability to mutate is responsible for the ability of some viruses to change slightly in each infected person, making treatment difficult.‘

Notably, all viruses are distinguished by an inability to reproduce on their own. ‘They infect the cells of living organisms from plants to people, hijacking the host’s cellular machinery to reproduce itself.‘

Bacteria, on the other hand are defined as ‘single-celled microorganisms that differ from all other organisms (the eukaryotes) in lacking a true nucleus and organelles such as mitochondria, chloroplasts, and lysosomes. Their genetic material consists of a single loop of double-stranded DNA, whereas the genetic material of eukaryotes consists of multiple chromosomes, which are complex structures of DNA and protein.‘

Note: ‘Genetic material can be transferred between bacteria by three processes: transformation (absorption of naked DNA), transduction (transfer by a virus), and conjugation (transfer by independently replicating DNA molecules, called plasmids, which can be inserted into the bacterial DNA).‘

According to the Mayo Clinic, ‘In some cases, it may be difficult to determine whether a bacterium or a virus is causing your symptoms. Many ailments — such as pneumonia, meningitis and diarrhea — can be caused by either type of microbe (Viral or Bacterial infection).‘

Such an accumulation of overlapping & contradictory scientific evidence begs the question – has the Medical community misdiagnosed Ebola?

Are we actually dealing with a virus here, or a bacterial strain, or in fact, a composite form of virus/bacteria hybrid?

On close examination, it quickly becomes apparent that MenAfriVac® was rushed into circulation, a cost-cutting measure, without any adequate testing on its potential carcinogenic properties – the end result, a plethora of cases involving post-vaccination neurological damage; notably Guillain–Barré syndrome (GBS).

‘There have been confirmed case reports of Guillain-Barre Syndrome (GBS), a serious neurologic disorder of peripheral nerves…the most alarming reports were from the village of Guoro in Northern Chad of Africa where at least 40 out of five hundred children that received MenAfrivac vaccine aged between 7 and 18 became paralyzed and these children also suffered convulsions and hallucinations.‘ National Agency for Food & Drugs (NAFDAC)

‘None of the 137 serious adverse events (including 14 deaths) reported in the vaccine studies were assessed to be related to the study vaccines.‘ Review of safety profile on meningococcal A conjugate vaccine from clinical trials, WHO

‘This meningococcal A conjugate vaccine was developed specifically to combat epidemic meningitis in sub-Saharan Africa by a consortium of partners including CDC, PATH, WHO, FDA, the Health Protection Agency and the National Institute for Biological Standards and Control, with funding from the Bill & Melinda Gates Foundation.‘ CDC

The Meningitis Vaccine Project (MVP): ‘Created in June 2001 by a grant from the Bill & Melinda Gates Foundation as a 10-year partnership between WHO and PATH (Program for Appropriate Technology in Health)‘

MVP Mission Statement: ‘to eliminate epidemic meningitis as a public health problem in sub-Saharan Africa through the development, testing, licensure, and widespread use of conjugate meningococcal vaccines.‘

The Meningococcal (Meningitis) Vaccine, MenAfriVac, is defined as a ‘Conjugate Vaccine‘ (containing bacterial capsular polysaccharide joined to a protein to enhance immunogenicity).

Note: ‘The combination of CP conjugate vaccines into a single multivalent injection, however, can result in competition among the different components and adversely affect the immunogenicity of any individual conjugate.‘ Fattom et al., Vaccine 17:126-33 (1999)

‘The MenAfrivac vaccine can be stored under Controlled temperature chain (CTC), up to 40°C for not more than four days immediately prior to administration, provided that the vaccine has not reached its expiry date and the vaccine vial monitor is still valid”. Unopened vaccine vials should be discarded at the end of the four days at 40°C. Reconstituted vaccine should be discarded within six hours.‘ WHO

Note: ‘It is difficult or impossible to reach the entire target population if vaccine is kept in the 2°C to 8°C cold chain.‘

‘There is no evidence that MenAfriVac can cause meningococcal meningitis. Clinical alertness to the possibility of co-incidental meningitis should be maintained.‘ MenAfriVac® (Manufacturer disclaimer)

MenAfriVac® Package insert ‘Each vial contains a lyophilised powder of meningococcal group A polysaccharide conjugated to tetanus toxoid protein and excipients. Each ampoule contains the diluent with aluminium phosphate as adjuvant (the amount does not exceed 1.25 mg per single human dose) and thimerosal (0.01%) as preservative.‘

Note: ‘A small dose of mercury that kills 1 in 100 rats and a dose of aluminum that will kill 1 in 100 rats, when combined have a striking effect: all the rats die. Doses of mercury that have a 1 percent mortality will have a 100 percent mortality rate if some aluminum is there.‘ Dr. Donald Miller, M.D.

The Vaccine components include: ‘Tetanus toxoid + Hydrazine = TT-NH2 & Polysaccharide + NaIO4 = Activated PS.‘

1. Tetanus Toxoid Carrier Protein: ‘Tetanus toxin C-fragment consists of the C-terminal portion of the heavy chain of tetanus toxin…retains the binding and internalization properties associated with intact tetanus toxin. These properties make C-fragment and its conjugates useful in tracing nerve fiber connections in the CNS. List Labs produces C-fragment, Product # 193, from enzyme digested Clostridium tetani toxin.‘

‘Clostridium tetani culture is grown in a peptone-based medium containing an extract of bovine muscle tissue and detoxified with formaldehyde. The bovine muscle tissue used in this medium is US sourced. The detoxified material is then purified by serial ammonium sulfate fractionation and diafiltration, followed by sterile filtration. The toxoid is adsorbed to aluminum potassium sulfate (alum). The adsorbed toxoid is diluted with physiological saline solution (0.85%).

Tetanus Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is supplied in a unit dose 0.5 mL vial, which contains a trace amount of thimerosal [(mercury derivative), (≤0.3 μg mercury/dose)] from the manufacturing process. Tetanus Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is also supplied in a 5 mL vial, which contains the preservative thimerosal [(mercury derivative), (25 μg mercury/dose)].‘

Note: ‘The structural gene for tetanus toxin has been cloned and sequenced.‘ Fairweather et al., J. Bacteriol. 165: 21-27 (1986); Fairweather et al., Nuci. Acid Res. 14: 7809-7812 (1986).

2. Hydrazine: ‘Because of the toxicity of hydrazine in humans, it is necessary to monitor this substance’s process control step during the vaccine production.‘

3. NaIO4 9 (Sodium metaperiodate): ‘The substance is toxic to lungs, mucous membranes. Repeated or prolonged exposure to the substance can produce target organs damage.‘

Vaccine excipients: ‘mannitol, sucrose and Tris (hydroxymethyl) aminomethane.‘

Tris (hydroxymethyl) aminomethane: ‘May cause liver and kidney damage. The toxicological properties of this material have not been fully investigated. Hygroscopic (absorbs moisture from the air). Causes eye and skin irritation. May cause respiratory tract irritation.‘

‘GACVS (Global Advisory Committee on Vaccine Safety) supported WHO’s technical guidance that MenAfriVac should be offered to pregnant and lactating women from the African meningitis belt during any stage of pregnancy or lactation, while recommending that a plan be developed to follow up women in antenatal or obstetric clinics, and to monitor pregnancy outcomes by making appropriate comparisons with unvaccinated pregnant women.‘ Extract from report of GACVS meeting of 11-12 June 2014, published in the WHO Weekly Epidemiological Record on 18 July 2014



The origins of Ebola are linked to a deadly Malaria vaccine formula called ‘Chloroquine’ – which affected only those individuals locally who received the Malaria treatment; while also virally shedding to others in the community who had close contact with the infected (host) vaccinee. In all cases, The typical onset of symptoms leading to Hemorrhagic Fever (what was eventually diagnosed as Ebola) began to manifest within 5 days after receiving the toxic shot.

‘Between 1 September and 24 October 1976, 318 cases of acute viral haemorrhagic fever occurred in northern Zaire. The outbreak was centred in the Bumba Zone of the Equateur Region and most of the cases were recorded within a radius of 70 km of Yambuku, although a few patients sought medical attention in Bumba, Abumombazi, and the capital city of Kinshasa, where individual secondary and tertiary cases occurred. There were 280 deaths, and only 38 serologically confirmed survivors.

The index (first reported) case in this outbreak had onset of symptoms on 1 September 1976, five days after receiving an injection of chloroquine for presumptive malaria at the outpatient clinic at Yambuku Mission Hospital (YMH). He had a clinical remission of his malaria symptoms.

Within one week several other persons who had received injections at YMH also suffered from Ebola haemorrhagic fever, and almost all subsequent cases had either received injections at the hospital or had had close contact with another case. Most of these occurred during the first four weeks of the epidemic, after which time the hospital was closed, 11 of the 17 staff members having died of the disease.

All ages and both sexes were affected, but women 15-29 years of age had the highest incidence of disease, a phenomenon strongly related to attendance at prenatal and outpatient clinics at the hospital where they received injections. The overall secondary attack rate was about 5%, although it ranged to 20% among close relatives such as spouses, parent or child, and brother or sister.‘ Report of an International Commission, World Health Organization, 1978

1. ‘The index (first reported) case in this outbreak had onset of symptoms on 1 September 1976, five days after receiving an injection of chloroquine for presumptive malaria ‘

2. ‘Within one week several other persons who had received injections at YMH also suffered from Ebola haemorrhagic fever.’

3. ‘almost all subsequent cases had either received injections at the hospital or had had close contact (vaccine-derived viral shedding) with another case.’

Note to those Doctors & Virologists unaware of this crucial information: Chloroquine (“drug” treatment for Malaria) was indeed INJECTED into those Africans who subsequently contracted Ebola (typical symptoms manifesting within 5-7 days). It has since been given primarily in a pill form; accepting those ‘acute attacks of malaria when the patient is unable to swallow’. However in 1976, in Zaire, Africa, safety protocols were unavailable or ignored – with dire consequences.

The following (severe) side effects are associated with chloroquine injection; Abnormal Heart Electrical Signals, Abnormal Liver Function Tests, Abnormally Low Blood Pressure, Acquired Decrease of All Cells in the Blood, Decreased Blood Platelets, Decreased Neutrophils a Type of White Blood Cell, Deficiency of Granulocytes a Type of White Blood Cell, Disease of the Muscle of the Heart with Enlargement, Hepatitis, Increased Eosinophils in the Blood, Life Threatening Allergic Reaction, Low Blood Counts due to Bone Marrow Failure, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis.‘ WebMD




Ebola Virus: ‘Generally, the abrupt onset of Ebola haemorrhagic fever follows an incubation period of 2–21 days (mean 4–10) and is characterised by fever, chills, malaise, and myalgia. The subsequent signs and symptoms indicate multisystem involvement and include systemic (prostration), gastrointestinal (anorexia, nausea, vomiting, abdominal pain, diarrhoea), respiratory (chest pain, shortness of breath, cough, nasal discharge), vascular (conjunctival injection, postural hypotension, oedema), and neurological (headache, confusion, coma) manifestations.

Haemorrhagic manifestations arise during the peak of the illness and include petechiae, ecchymoses, uncontrolled oozing from venepuncture sites, mucosal haemorrhages, and post-mortem evidence of visceral haemorrhagic effusions. A macropapular rash associated with varying severity of erythema and desquamate can often be noted by day 5–7 of the illness; this symptom is a valuable differential diagnostic feature and is usually followed by desquamation in survivors. Abdominal pain is sometimes associated with hyperamylasaemia and true pancreatitis. In later stages, shock, convulsions, severe metabolic disturbances, and, in more than half the cases, diffuse coagulopathy supervene.‘ Heinz Feldmann, MD and Thomas W Geisbert, PhD, The Lancet

‘The four Ebola strains are termed as follows: Zaire, Sudan, Tai Forest, and Bundibugyo virus, with Zaire being the most lethal strain. A fifth strain termed Reston has been found in the Philippines. The strain infects primates, pigs, and humans and causes few if any symptoms and no deaths in humans. Most outbreaks of the more lethal strains of Ebola have occurred in Africa and mainly in small- or medium-sized towns.‘ MedicineNet

”The mean incubation period was estimated to be 12.7 days (standard deviation 4.31 days), indicating that about 4.1% of patients may have incubation periods longer than 21 days.‘ Incubation Period of Ebola Hemorrhagic Virus Subtype Zaire

‘An important distinction of Ebola virus from other Mononegavirales is the production of a soluble glycoprotein, which is the primary product of the GP gene, and gets secreted to large quantities from infected cells.‘ National Institutes of Health



The epidemiology of Yellow Fever also bares striking resemblance to Ebola, given the distinct characteristics & potential virulence common to each virus:

1. an incubation period lasting upwards of 1 week (‘Physical symptoms usually appear 3–6 days after’)

2. an array of flu-like symptoms during the initial stages, including (‘fever, muscle pain, particularly backache, headache, shivering, loss of appetite, and nausea or vomiting’)

3. leading to varying degrees of internal “blackish” bruising & widespread hemorrhaging (‘gastrointestinal bleeding, haematuria, skin petechiae, ecchymoses,’)

4. followed by rapid systemic deterioration, marked by Kidney failure, often leading to death (‘About 20%–50% of patients with hepato-renal failure die, usually 7–10 days after the onset of disease’)

‘Typically, the disease onset is abrupt, with fever, muscle pain, particularly backache, headache, shivering, loss of appetite, and nausea or vomiting. Congestion of the conjunctivae and face are common, as well as relative bradycardia in the presence of fever. The patient is usually viraemic during this period, which lasts for approximately 3–6 days.

In approximately 15% of infected persons, the illness recurs in more severe form after a brief remission of 2–24 hours. Symptoms include fever, nausea, vomiting, epigastric pain, jaundice, renal insufficiency, and cardiovascular instability. A bleeding diathesis can occur causing gastrointestinal bleeding, haematuria, skin petechiae, ecchymoses, epistaxis, and bleeding from the gums and needle-puncture sites.



Physical findings include scleral and dermal jaundice, haemorrhages at different sites and epigastric tenderness without hepatic enlargement. The haemorrhagic manifestations are caused by reduced synthesis of clotting factors as well as by a consumptive coagulopathy.

About 20%–50% of patients with hepato-renal failure die, usually 7–10 days after the onset of disease. Patients surviving YF may experience prolonged weakness and fatigue, but healing of the liver and kidney injuries is usually complete.‘ WHO Position Paper – June 2011

‘Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event associated with administration of the yellow fever vaccine. YEL-AVD is an illness similar to wild-type yellow fever, in which the vaccine virus proliferates in multiple organs, causing multiple organ dysfunction syndrome or multiorgan failure and death in at least 60% of cases. Initial symptoms of YEL-AVD are nonspecific and can include the following: fever, malaise, headache, myalgia, vomiting, and diarrhea. More severe cases can progress to hepatic (liver), renal (kidney), or respiratory insufficiency or failure; hypotension; thrombocytopenia; and coagulopathy (inability to regulate clotting causing massive hemorrhaging).‘ CDC – History, Epidemiology, and Vaccination Information

‘Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is clinically indistinguishable from wild-type yellow fever illness. Most YEL-AVD reports describe patients with fever and multiple organ system failure, and often death (17 deaths/29 cases worldwide).‘ The American Journal of Tropical Medicine and Hygiene

‘The present YF vaccines are based on a wild-type YF virus isolated in Ghana in 1927. Numerous mutations in the viral structural and non-structural genes have led to the attenuated variant 17D. This attenuated vaccine virus exists in 2 sub-strains (17D-204 and 17DD) which share 99.9% sequence homology. Nucleotide sequencing has shown differences between these vaccine strains and the wild-type Asibi strain, affecting 20 amino acids. Virus with the resulting phenotype is non-transmissible by mosquitoes. Both sub-strains are used in vaccines prepared by culturing the virus in embryonated eggs. The vaccine contains sorbitol and/or gelatine as a stabilizer and is lyophilized. No preservative is added.‘ WHO Position Paper on Yellow Fever Vaccine

Based on preliminary reports from field doctors in Africa, Doctors in Belgium examining blood samples from the 1976 Zaire outbreak were initially expecting Yellow Fever, NOT Ebola. ‘The researchers in Zaire who had sent it couldn’t identify the virus, simply labeling it, “Yellow Fever?”‘

In 1994, another Ebola outbreak (in northeastern Gabon, bordering the Congo) was mistaken for Yellow Fever, this time based on actual clinical findings – ‘Yellow fever (YF) virus was first diagnosed in serum by use of polymerase chain reaction followed by blotting,‘

This subsequently led to the institution of a Yellow Fever vaccination campaign. It was only later, that doctors determined: ‘some aspects of this epidemic were atypical of YF infection, so a retrospective check for other etiologic agents was undertaken. Ebola (EBO) virus was found to be present concomitantly (joined together/co-mingling) with YF (Yellow Fever) virus in the epidemic.‘

This current version of Ebola virus had 40 years to spread to outlying regions. It never did.

How did the Zaire strain of Ebola get to West Africa from about 3,500 km away from where it was first identified in 1976?

How does a virus that has remained dormant, relatively stable, isolated, suddenly manifest in areas well outside its traditional territory?

With a little help from the Centres for Disease Control (proliferation), that’s how.

Even the CDC Director admits they are baffled by the unprecedented concentration of cases outside the typical range,

‘For more than four decades, Ebola virus had only been diagnosed in Central or Eastern Africa. Then late this past March, the first cases of Ebola began appearing in a surprising part of the continent. The outbreak in Guinea was the first sign that the virus had made the jump across the continent. Ebola then spread quickly to Sierra Leone and Liberia, and then to Nigeria.‘ Tom Frieden, MD, Director, US Centers for Disease Control and Prevention, Atlanta, Georgia

‘No virus that causes disease in humans has ever been known to mutate to change its mode of transmission.‘ Mainstream Media misinformation

In truth, no virus is fully modified or attenuated or killed during the vaccine manufacturing process. All vaccines, by their very nature, play off each other, generate a “synergistic” chain-reaction triggering further (more insidious) infections & disorders. In many cases the very signature disease/disorder they claim to protect you against is PRECISELY that which they inadvertently spread; albeit a more virulent “transforming” strain of the primary pathogen.
Essentially, ALL Viral vaccines become “weaponized” through the various stages of Vaccine development; further metastasizing in the vaccine host: ‘Mutations that can occur when the vaccine virus replicates in the body may result in more a virulent strain.‘

In practical terms, a synergy factor inevitably occurs when multiple ingredients such as heavy metals, live (attenuated/modified) viruses/or strands of DNA-RNA “heat treated virus”, antibiotic(s), formaldehyde, detergent(s), diploid cells (aborted fetal tissue), mycoplasma, phenol dye & excipient buffers are combined together in a vial mixture, generating a bio-active (electrical) chemical reaction – worsened by combinations with post-vaccination Prescription drugs; frequently seen as the tipping point which triggers/hastens an escalation of adverse neurological symptoms, a cascading degeneration (reduced Mitochondrial & Metabolic capacity) leading to varying degrees of auto-immune (multi-systemic) failure in the body.



‘The viruses are generally attenuated on the basis of only a few mutations and have a considerable chance of reverting to wild-type thereby causing the very disease in vaccine recipients that they are aimed to prevent.‘ GIT Laboratory Journal

‘Despite the advantages of live, attenuated vaccines, there are some downsides. It is the nature of living things to change, or mutate, and the organisms used in live, attenuated vaccines are no different. The remote possibility exists that an attenuated microbe in the vaccine could revert to a virulent form and cause disease.’ US National Institute of Allergy and Infectious Diseases

‘One concern that must be considered is the potential for the vaccine virus to revert to a form capable of causing disease. Mutations that can occur when the vaccine virus replicates in the body may result in more a virulent strain. This is very unlikely, as the vaccine virus’s ability to replicate at all is limited; however, it is taken into consideration when developing an attenuated vaccine.

It is worth noting that mutations are somewhat common with the oral polio vaccine (OPV), a live vaccine that is ingested instead of injected. The vaccine virus can mutate into a virulent form and result in rare cases of paralytic polio. For this reason, OPV is no longer used in the United States, and has been replaced on the Recommended Childhood Immunization Schedule by the inactivated polio vaccine (IPV).‘ College of Physicians, Philadelphia

“One vaccine decreases cell-mediated immunity by 50%, two vaccines by 70%…all triple vaccines (MMR, DTaP) markedly impair cell-mediated immunity, which predisposes to recurrent viral infections, especially otitis media, as well as yeast and fungi infections.” World-renowned Immunologist Dr. H.H. Fudenberg

‘Adventitious agents (mutable viruses/cross-contamination) could theoretically enter a viral vaccine through any of these ingredients (cell substrates, vaccine seed, tissue culture reagents, stabilizers).’ FDA



The United States Government (Secretary of the Dept. of Health) secured the Patent & “de facto” proprietary rights to both Ebola & Yellow Fever Virus well before 2014. By extension, this gave the CDC (including National Institute of Allergy and Infectious Diseases & National Institutes of Health) carte blanche to experiment with either strain at will - a five year head-start on Ebola, and a fourteen year head-start on Yellow Fever.



The Ebola strain now circulating has clearly undergone significant mutagenic changes in a laboratory, alterations in the nucleotide sequencing that enable it to spread more quickly and efficiently that ever before.

Despite claims by the World Health Organization that Ebola is strictly a bloodborne pathogen which ‘spreads through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids’, evidence to the contrary, from multiple sources is challenging this Official narrative.

The Ebola Virus is now seemingly airborne.

‘Under conditions of the current study, transmission of ZEBOV (Zaire Ebola Virus) could have occurred either by inhalation (of aerosol or larger droplets), and/or droplet inoculation of eyes and mucosal surfaces and/or by fomites due to droplets generated during the cleaning of the room. Infection of all four macaques in an environment, preventing direct contact between the two species and between the macaques themselves, supports the concept of airborne transmission…the presence of Ebola virus antigen in some of the respiratory epithelial cells in the lungs of all macaques suggest that the airways were one of the routes involved in the acquisition of infection, consistent with previous reports..‘ National Centre for Foreign Animal Disease & National Microbiology Laboratory, Winnipeg, Canada 05 November 2012

Note: ‘Our findings support the hypothesis that airborne transmission may contribute to ZEBOV (Zaire Ebola Virus) spread, specifically from pigs to primates, and may need to be considered in assessing transmission from animals to humans in general.‘



The Ebola & Aids (HIV) Virus share one precise common thread, a key protein capable of shutting down the body’s Immune system, by disabling what are known as T-cells.

‘T cells contribute to immune defenses in two major ways: Some direct and regulate immune responses…by communicating with other cells. Some stimulate nearby B cells to produce antibodies, others call in microbe-gobbling cells called phagocytes, and still others activate other T cells.‘ National Institute of Allergies & Infectious Diseases

“You know the (Ebola) virus, it’s like ‘shock and awe.’ It’s like over within a week. I mean the virus grows very quickly and it kills off the very cells you need to mount your immune response.” Dr. Kartik Chandran, Whitehead Institute, Harvard Medical School, Albert Einstein College of Medicine



‘Ebola virus’s ability to enter cells is reminiscent of the Trojan Horse used by the ancient Greeks to defeat their archenemies. Ebola virus binds to the host cell’s outer membrane, and a portion of host cell membrane then surrounds the virus and pinches off, creating an endosome — a membrane-bound bubble inside the cell (see image). Endosomes carry their viral stowaways deep within the cell and eventually mature into lysosomes — tiny enzyme-filled structures that digest and recycle cellular debris.

The viruses captive in the lysosome manage to escape destruction by exploiting components of the cell to gain entry to the cytoplasm, the substance between the cell membrane and the nucleus where the virus can replicate. But the identities of many of these components have remained unknown.‘ Albert Einstein College of Medicine, 08/24/2011

‘Our screen uncovered 67 mutations disrupting all six members of the homotypic fusion and vacuole protein-sorting (HOPS) multisubunit tethering complex, which is involved in the fusion of endosomes to lysosomes, and 39 independent mutations that disrupt the endo/lysosomal cholesterol transporter protein Niemann–Pick C1 (NPC1).‘ Ebola virus entry requires the cholesterol transporter Niemann–Pick C1, International Weekly Journal of Science, 08/24/2011

‘Niemann-Pick disease type C1 is a lysosomal storage disease caused by a mutation in the NPC1 gene. NPC1 encodes an integral membrane protein containing sequence motifs thought to be consistent with a role in intracellular transport of cholesterol to post-lysosomal destinations. Mutations in NPC1 have also been linked with obesity, HIV-AIDS, and Ebola virus.‘

A 1972 report (Bulletin 47) issued by the World Health Organization referred to an immune virus requested which would selectively destroy the Human T Cell System, to be distributed in conjunction with a Nationwide vaccination program “to observe the results”.

This coincided precisely with the extensive Small Pox vaccination program in central Africa & Hepatitis B program (Africa & throughout the Americas etc)– shortly preceding the outbreak of Aids in Africa, America & elsewhere. The determining factor most common in Aids (and Ebola) victims is the breakdown of the T Cell System in the body. Just another disturbing coincidence.

“There is a blueprint, the 1971 research logic of the US Special (HIV) Virus program…a virus that only targets certain persons – as is evidenced by the epidemiology. Here is the final phase, the clinical trials. It was placed in the Small Pox vaccines that went to Africa. Every epidemiology that we have regarding the beginning of HIV & Aids shows that as Small Pox ended, HIV & Aids began in mass in Africa. HIV and Aids began in mass in the late 1970’s as a result of the US Special Virus program and the complementation of that vaccine (Small Pox vaccine program in Africa) with this special virus (T-Cell disruptor component – authorized by Henry Kissinger) that shows the development of HIV over a period from 1962-1978.

How dare you have a Federal Virus program that precedes the greatest onslaught of murder in the history of the world, and you don’t want to acknowledge the program, and you certainly don’t want to review it. The people demand it. This Federal program lies at the heart of HIV & Aids and it needs to be reviewed.” Dr. Boyd Graves (formal testimony given shortly before his premature death)

The whole criteria for identifying Ebola is, in and of itself, skewed. These viruses have undergone so many changes, through decades of (unmonitored) laboratory experimentation, re-engineering & chemical synthesis and genetic replication via vaccine programs, they no longer resemble anything close to the naturally occurring, “wild strains” previously found in the environment.

Irrespective of whether we are confronting a vaccine-derived hybrid (mutagenic) strain of bacterial Meningitis here, a vaccine-derived hybrid strain of Yellow Fever, a deadly variant of Malaria, or, in fact, a laboratory-derived hybrid strain of the Ebola Virus (essentially a composite of the laboratory produced Aids syndrome) the so-called vanguard of Health “Authority”, chiefly the CDC & WHO, are purposefully focusing on a Vaccine & Drug response to this current health crisis, while ignoring the fact that the Ebola Virus can only thrive in a body starved of Selenium – thereby depriving our communities of critical information in a time of national emergency.

The Ebola Virus can ONLY thrive in a body starved of Selenium. In fact ALL Ebola Virus victims, those who typically succumb to Hemorrhagic fever, viral replication (infected blood) and excessive hemorrhaging of the blood leading to death, concurrently suffer from acute malnutrition, marked by extreme Selenium deficiency in the body.

Selenium is an essential trace mineral & anti-oxidant, a primary stop-gap which enables the human body to adapt to (overcome) any viral infections circulating in the environment, and helps to prevent the typical Ebola-type symptoms (chiefly excessive hemorrhaging) from taking hold and ultimately killing the host (vaccinee).

Selenium helps regulate Thyroid function and your overall metabolism, primarily by preventing an over-abundance of free-radicals in the body, converts T4 (free thyroxine) to T3 (triiodothyronine), supported by Vitamin E. Selenium deficiency also inhibits the body’s ability to process nutrients effectively.

Natural sources rich in Selenium include Brazil nuts, Sunflower seeds & Food Grade Diatomaceo​us Earth (“fossilized shell flour”).

Note: Selenium is a major piece in the puzzle; however, given the insidious nature of Ebola, proper guidelines respecting an overall holistic health protocol must be followed – therefore a balanced approach combining all essential trace minerals & antioxidants, including phytonutrients, is needed.

‘Ebola is classified as a “hemorrhagic fever” virus, and produces the characteristic hemorrhaging due to the formation of blood clots (“disseminated intravascular coagulation”), leading to the obstruction and rupture of small blood capillaries.

SOURCE